IL6 and COVID-19: The risk of severe infection in patients with diabetes and COVID-19 is associated with an increase in angiotensin-converting enzyme 2 (ACE 2), impaired T Cell function, and increased interleukin-6 (IL-6), which promotes COVID-19 infection due to increased viral entry and an impaired immune response [3].